SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice

• Main Authors: Jeroen Pollet (Author), Wen-Hsiang Chen (Author), Leroy Versteeg (Author), Brian Keegan (Author), Bin Zhan (Author), Junfei Wei (Author), Zhuyun Liu (Author), Jungsoon Lee (Author), Rahki Kundu (Author), Rakesh Adhikari (Author), Cristina Poveda (Author), Maria Jose Villar (Author), Ana Carolina de Araujo Leao (Author), Joanne Altieri Rivera (Author), Zoha Momin (Author), Portia M. Gillespie (Author), Jason T. Kimata (Author), Ulrich Strych (Author), Peter J. Hotez (Author), Maria Elena Bottazzi (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low- and middle-income countries. Here, we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast (Pichia pastoris), as a suitable vaccine candidate agains...